Inquiry Basket
Loading ......
Antibody drugs are a relatively new type of biomacromolecule drug, mainly humanized recombinant monoclonal antibodies. Therefore, their application in diseases can lead to effectiveness issues for individual therapists. Currently, a large number of clinical and pharmaceutical companies are engaged in this research. Therefore, detecting the blood concentration of antibody drugs and the level of antibodies produced by the body against antibody drugs is of great significance for guiding treatment and personalized medication.
Figure 1. Production of Monoclonal Antibodies. (Ramadhin, Jessica, et al.,2020)
The rapid development of therapeutic monoclonal antibodies plays a crucial role in the treatment of various diseases, mainly tumors, in humans. In order to reduce hypersensitivity reactions caused by mouse derived antibodies, therapeutic monoclonal antibodies have evolved from modified antibodies and humanized antibodies to whole human antibodies. With the continuous development of biotechnology, it is believed that the prospects of humanized monoclonal antibodies will become increasingly broad. Monoclonal antibodies are the commonly used immunotherapy drugs for various diseases such as cancer and infections. Monoclonal antibodies in immunotherapy can specifically bind to specific proteins or cells, thereby enhancing the immune system's ability to clear diseased cells.
Figure 2. Development of therapeutic antibodies for the treatment of diseases. (Lu, Ruei-Min, et al.,2020)
Monoclonal antibodies are highly uniform antibodies produced by a single B cell clone, targeting only a specific antigenic epitope. Usually, hybridoma technology is used for preparation. Hybridoma antibody technology is based on cell fusion technology, which fuses sensitized B cells with the ability to secrete specific antibodies and myeloma cells with unlimited proliferation ability to form B cell hybridomas. Advantages of monoclonal antibodies: high purity, high sensitivity, strong specificity, minimal cross reactivity, and low preparation cost. Enzyme linked immunosorbent assay (ELISA) is the most commonly used immunological diagnostic technique. Through ELISA, technicians can screen and quantify target antigens in liquid samples such as blood and body fluids. There are various types of ELISA, and the commonly used one is the direct ELISA. The antigen to be detected is fixed on the surface of a solid carrier, and a monoclonal antibody conjugated with a reporter enzyme or fluorescent dye is added. Then, a substrate (usually a chromogenic substrate) is added to generate a detectable signal.
Monoclonal antibody detection ELISA kits have wide applications in various fields:
Clinical Diagnosis
ELISA kits are widely used in clinical diagnosis to detect infectious diseases, autoimmune diseases, and cancer biomarkers. For example, monoclonal antibodies are used to detect HIV, and ovarian cancer markers such as HE4. These test kits are also used to detect pregnancy by detecting human chorionic gonadotropin (HCG).
Research and Development
In the study, ELISA kits are used to investigate the expression and function of proteins, including coagulation factors, cytokines, and hormones. For example, monoclonal antibodies are used to detect factor XIII, antithrombin, and prothrombin in blood samples. These kits are also used to study exosomes, RNA, and DNA in various biological systems
Monoclonal antibody detection ELISA kit is a powerful tool in the field of immunoassay. Their ability to detect specific antigens with high precision and reliability makes them indispensable in clinical diagnosis, research, and biotechnology. With the continuous development of this field, these test kits will play an increasingly important role in early detection of diseases, monitoring of treatment responses, and advances in biomedical research.
Remolumab is a monoclonal antibody drug that increases the overall survival of metastatic gastric cancer patients after first-line treatment. Remolumab is a human IgG1 monoclonal antibody that blocks the vascular endothelial growth factor receptor 2 (VEGFR-2), which prevents angiogenesis. VEGFR stimulation also mediates signals required for angiogenesis, and is closely related to cancer, so it is also a drug target. Other drugs that target VEGFR-2 bind to other epitopes in the extracellular domain of VEGFR-2, so they can bind to some VEGF ligands but not others. TDM is a clinical practice that monitors specific drugs at predetermined time intervals to maintain a constant concentration in the blood of patients to achieve individualized dosing strategies. Indications for drug monitoring include: drug efficacy, drug compliance, drug-drug interaction, drug toxicity, and treatment discontinuation monitoring. In addition, drug monitoring can help detect medication non-compliance in non-compliant patients.
Therapy Area of Remolumab
Related Products
The enzyme-linked immunosorbent assay kit can be used to measure drug concentration and anti drug antibodies. The Creative Diagnostics Ramolumab enzyme-linked immunosorbent assay product line is as follows:
| ELISA Kit | Application |
| Anti-Ramucirumab ELISA Kit | Qualitative Antibodies to Ramucirumab ELSA has been especially developed for the qualitative analysis of antibodies to ramucirumab in serum and plasma samples. |
Ecuzumab is a monoclonal antibody preparation used for the treatment of rare diseases such as cholecystitis bridging nephritis, complement related nephropathy caused by gene mutations, and complement mediated hemolytic anemia. The drug was first approved for market in the European Union and the United States in 2007. It is an artificially synthesized immunoglobulin G1 (IgG1) antibody and is widely regarded as a milestone in the history of modern medicine. In 2018, Ecuzumab was also approved by the FDA for the treatment of critical vascular hemoglobinuria (PNH). Among them, hemoglobinuria (PNH) is a rare blood disease, estimated to affect only 2-3 people per 1 million population.
For patients who need to use this type of medication for a long time, the burden of Ecuzumab remains heavy. Moreover, some patients who use Ecuzumab may develop resistance, and long-term use of Ecuzumab can lead to the accumulation of C5 in the body, which can cause breakthrough hemolytic acute attacks in patients. Therefore, the detection kit for Ecuzumab has arrived!
| ELISA Kit | Descriptions |
| Eculizumab ELISA Kit | Enzyme immunoassay for the specific and quantitative determination of free Eculizumab (Soliris) in serum, plasma and cell culture samples. |
| Anti-Eculizumab (SOLIRIS™) ELISA Kit | The Anti-Eculizumab (SOLIRIS™) ELISA Kit is used as an analytical tool for quantitative determination of Anti-Eculizumab in serum and plasma. |
| Anti-Eculizumab monoclonal antibody | Suitable for use to measure free Eculizumab in patient samples. Recommended Working Concentration: 0.01-1 μg/ml |
Monoclonal antibody detection ELISA kit is a powerful tool in the field of immunoassay. Their ability to detect specific antigens with high precision and reliability makes them indispensable in clinical diagnosis, research, and biotechnology. With the continuous development of this field, these test kits will play an increasingly important role in early detection of diseases, monitoring of treatment responses, and advances in biomedical research.
References
Loading ......
